Specialty Pharmacy Management
Expert-defined terms from the Certificate in Pharmacy Benefit Management course at London School of Planning and Management. Free to read, free to share, paired with a professional course.
Adverse Event Reporting – concept #
pharmacovigilance. Related terms: Safety monitoring, risk management. Explanation: Systematic collection and analysis of negative drug reactions in specialty patients. Example: A biologic for rheumatoid arthritis causes severe infusion reactions; the pharmacy documents and submits the report to FDA. Challenges: Timely data capture, patient confidentiality, and integration with electronic health records.
Benefit Design – concept #
plan architecture. Related terms: Formulary tiering, cost-sharing. Explanation: Structuring pharmacy benefits to balance clinical effectiveness and financial sustainability. Example: Tier‑1 includes generic oral meds, Tier‑2 specialty oral agents, Tier‑3 high‑cost injectables. Challenges: Aligning incentives across payers, providers, and patients while maintaining access.
Capitation – concept #
fixed payment model. Related terms: Risk-based contracts, per member per month (PMPM). Explanation: A set fee paid to a specialty pharmacy for managing a defined patient population regardless of service volume. Example: A health plan pays $200 PMPM for all oncology patients managed by a specialty pharmacy. Challenges: Forecasting utilization, ensuring quality of care, and preventing under‑service.
Clinical Prior Authorization – concept #
pre‑approval process. Related terms: Utilization management, formulary restriction. Explanation: Mandatory review of clinical data before a specialty medication is dispensed. Example: An insurer requires documentation of failed standard therapy before approving a Janus kinase inhibitor. Challenges: Provider burden, delays in therapy initiation, and maintaining up‑to‑date criteria.
Drug Utilization Review (DUR) – concept #
medication assessment. Related terms: Retrospective review, prospective review. Explanation: Systematic evaluation of prescribing patterns to ensure appropriate use of specialty drugs. Example: A DUR identifies patients on a high‑cost biologic without required lab monitoring. Challenges: Data integration, resource intensity, and clinician engagement.
Electronic Prior Authorization (ePA) – concept #
digital workflow. Related terms: Health IT integration, interoperable platforms. Explanation: Automated electronic submission of prior‑authorization requests within pharmacy or EMR systems. Example: A prescriber clicks “Submit ePA” in the EHR, and the request routes to the insurer instantly. Challenges: Varying standards, system compatibility, and training needs.
Formulary Management – concept #
medication list control. Related terms: Tiered formularies, therapeutic interchange. Explanation: Ongoing process of selecting and updating the list of covered specialty drugs. Example: Adding a new CAR‑T therapy to the oncology formulary after health‑economic analysis. Challenges: Balancing clinical evidence, cost constraints, and patient access.
Health Technology Assessment (HTA) – concept #
value evaluation. Related terms: Cost‑effectiveness analysis, outcomes research. Explanation: Systematic appraisal of clinical and economic data to inform coverage decisions for specialty therapies. Example: An HTA concludes that a new hepatitis C cure is cost‑effective at $45,000 per cure. Challenges: Data gaps, methodological variability, and stakeholder consensus.
Indication‑Based Pricing – concept #
price differentiation. Related terms: Value‑based contracting, outcome‑based reimbursement. Explanation: Setting drug prices according to specific approved indications, reflecting varying therapeutic value. Example: A monoclonal antibody priced higher for metastatic disease than for earlier‑stage cancer. Challenges: Tracking indication usage, regulatory acceptance, and pricing complexity.
Joint Commission Accreditation – concept #
quality standards. Related terms: Pharmacy certification, compliance audit. Explanation: Accreditation body that evaluates specialty pharmacy processes for safety and quality. Example: A specialty pharmacy undergoes a site visit to verify sterile compounding procedures. Challenges: Maintaining continuous compliance, resource allocation, and documentation burden.
Key Performance Indicators (KPIs) – concept #
metric tracking. Related terms: Dashboard reporting, quality measures. Explanation: Quantifiable metrics used to assess specialty pharmacy performance. Example: KPI – “average time from prescription receipt to drug delivery” target ≤ 48 hours. Challenges: Data accuracy, relevance to outcomes, and avoiding metric overload.
Letter of Authorization (LOA) – concept #
insurance permission. Related terms: Prior authorization, coverage confirmation. Explanation: Document from insurer granting a pharmacy permission to dispense a specialty medication. Example: An LOA authorizes dispensing a home‑infusion therapy for cystic fibrosis. Challenges: Ensuring timely receipt, handling renewals, and preventing lapses in therapy.
Medication Therapy Management (MTM) – concept #
clinical service. Related terms: Pharmaceutical care, patient counseling. Explanation: Structured, pharmacist‑led service to optimize therapeutic outcomes for specialty patients. Example: An MTM session reviews adherence barriers for a multiple‑sclerosis patient on an injectable disease‑modifying agent. Challenges: Reimbursement, documentation, and patient engagement.
Network Adequacy – concept #
provider accessibility. Related terms: Specialty pharmacy contracts, geographic coverage. Explanation: Ensuring sufficient specialty pharmacy locations to meet patient needs. Example: A plan must have at least one specialty pharmacy within 30 miles of each member. Challenges: Rural access, contract negotiations, and travel barriers.
Outcomes‑Based Contracting – concept #
risk‑sharing agreement. Related terms: Performance guarantees, rebate structures. Explanation: Contracts tying payment for a specialty drug to agreed clinical outcomes. Example: A payer reimburses a portion of an oncology drug only if the patient achieves a complete response. Challenges: Defining measurable outcomes, data collection, and attribution.
Pharmacy Benefit Manager (PBM) – concept #
third‑party administrator. Related terms: Claims processing, formulary design. Explanation: Entity that manages prescription drug benefits on behalf of health plans, including specialty pharmacy oversight. Example: A PBM negotiates discounts with a biologic manufacturer and administers the specialty pharmacy network. Challenges: Transparency, conflict of interest, and regulatory scrutiny.
Quality Assurance (QA) – concept #
process control. Related terms: Standard operating procedures, continuous improvement. Explanation: Systematic activities to ensure specialty pharmacy services meet predefined standards. Example: Routine temperature monitoring of cold‑chain storage for monoclonal antibodies. Challenges: Resource intensity, audit fatigue, and keeping SOPs current.
Risk Evaluation and Mitigation Strategies (REMS) – concept #
regulatory program. Related terms: Safety monitoring, restricted distribution. Explanation: FDA‑mandated program to ensure benefits of a high‑risk specialty drug outweigh its risks. Example: A REMS requires prescriber certification before a gene‑therapy product can be dispensed. Challenges: Compliance tracking, patient education, and administrative burden.
Specialty Pharmacy Accreditation – concept #
certification standard. Related terms: CARF, URAC. Explanation: Formal recognition that a specialty pharmacy meets industry‑defined quality and safety criteria. Example: A pharmacy receives URAC accreditation after passing sterile compounding audits. Challenges: Cost of accreditation, ongoing compliance, and staff training.
Therapeutic Interchange – concept #
alternative therapy. Related terms: Formulary substitution, biosimilar switching. Explanation: Replacing a prescribed specialty drug with a clinically equivalent alternative to achieve cost savings. Example: Switching a patient from reference trastuzumab to a biosimilar version. Challenges: Provider acceptance, patient perception, and ensuring therapeutic equivalence.
Utilization Management (UM) – concept #
resource optimization. Related terms: Prior authorization, step therapy, DUR. Explanation: Strategies to control the appropriate use of specialty medications. Example: Implementing step therapy that requires trial of a lower‑cost oral agent before approving an injectable biologic. Challenges: Balancing cost containment with timely access, administrative workload, and patient outcomes.
Value‑Based Insurance Design (VBID) – concept #
benefit alignment. Related terms: Cost‑sharing reduction, outcome incentives. Explanation: Designing pharmacy benefits that lower out‑of‑pocket costs for high‑value specialty drugs. Example: Reducing copay for a hepatitis C cure to increase adherence and improve population health. Challenges: Identifying high‑value therapies, measuring impact, and managing budget impact.
Wholesale Acquisition Cost (WAC) – concept #
list price. Related terms: Average Wholesale Price (AWP), Net Price. Explanation: Manufacturer’s published price for a drug before discounts or rebates. Example: The WAC for a new CAR‑T therapy is $450,000 per treatment. Challenges: Transparency, variability across sources, and impact on formulary decisions.
ePrescribing – concept #
digital prescription. Related terms: Health information exchange, ePA. Explanation: Electronic transmission of a prescription from prescriber to pharmacy, facilitating faster specialty drug processing. Example: An oncologist sends an ePrescription for a checkpoint inhibitor directly to the specialty pharmacy. Challenges: Interoperability, alert fatigue, and ensuring complete clinical data.
Formulary Exception – concept #
coverage deviation. Related terms: Prior authorization, appeal process. Explanation: Process by which a prescriber requests coverage for a non‑formulary specialty drug based on clinical justification. Example: Requesting an exception for a rare disease therapy not listed on the formulary. Challenges: Lengthy review times, documentation requirements, and patient frustration.
Health Outcomes Research – concept #
effectiveness study. Related terms: Comparative effectiveness, real‑world evidence. Explanation: Investigation of the impact of specialty therapies on patient health status, quality of life, and healthcare utilization. Example: A study comparing real‑world survival of patients receiving two different HER2‑targeted agents. Challenges: Data heterogeneity, confounding variables, and long‑term follow‑up.
Intake Verification – concept #
order accuracy. Related terms: Prescription validation, eligibility check. Explanation: Initial review of a specialty prescription to confirm completeness, coverage, and clinical appropriateness. Example: Verifying that a patient’s insurance authorizes a home‑infusion service before processing the order. Challenges: High error rates, time pressure, and incomplete documentation.
Just #
In-Time (JIT) Inventory – concept: lean stocking. Related terms: Supply chain optimization, cold‑chain logistics. Explanation: Managing specialty drug inventory to minimize holding costs while ensuring timely availability. Example: Ordering a batch of gene‑therapy vials only after a confirmed prescription. Challenges: Forecasting demand, cold‑chain reliability, and regulatory constraints on drug shelf life.
Key Account Management (KAM) – concept #
strategic partnership. Related terms: Client relationship, portfolio stewardship. Explanation: Focused approach to managing relationships with high‑value health plans or provider groups for specialty pharmacy services. Example: A KAM team collaborates with an oncology network to streamline infusion logistics. Challenges: Aligning incentives, data sharing, and maintaining long‑term engagement.
Long‑Term Follow‑Up (LTFU) – concept #
post‑therapy monitoring. Related terms: Survivorship care, pharmacovigilance. Explanation: Ongoing assessment of patients after completion of a specialty treatment to capture outcomes and late effects. Example: Monitoring liver function for 12 months after a hepatitis B antiviral course. Challenges: Patient retention, data collection, and resource allocation.
Medication Reconciliation – concept #
medication list accuracy. Related terms: Transition of care, medication review. Explanation: Process of creating a complete, accurate medication list at each point of care transition for specialty patients. Example: Reconciling all biologics a patient is receiving before hospital discharge. Challenges: Fragmented records, patient recall, and time constraints.
National Drug Code (NDC) – concept #
identification number. Related terms: Barcode, product labeling. Explanation: Unique 11‑digit identifier assigned to each drug formulation, package size, and manufacturer. Example: The NDC for a 30‑ml vial of a monoclonal antibody is 12345‑6789‑01. Challenges: Maintaining up‑to‑date databases, avoiding duplicate entries, and ensuring correct billing.
On‑Boarding – concept #
patient enrollment. Related terms: Intake process, education program. Explanation: Initial steps to integrate a new specialty patient into pharmacy services, including education, device training, and insurance verification. Example: Providing a self‑injector training kit to a patient starting a new biologic. Challenges: Aligning schedules, ensuring comprehension, and managing paperwork.
Patient Assistance Programs (PAP) – concept #
financial support. Related terms: Copay assistance, manufacturer coupons. Explanation: Manufacturer‑sponsored initiatives that provide free or discounted specialty drugs to eligible patients. Example: A PAP supplies a high‑cost enzyme replacement therapy at no cost for qualifying patients. Challenges: Eligibility verification, regulatory compliance, and sustainability.
Quality‑Adjusted Life Year (QALY) – concept #
health economic metric. Related terms: Cost‑effectiveness, utility value. Explanation: Measure combining length of life with quality of health, used to assess value of specialty therapies. Example: A new oncology drug adds 0.5 QALYs at an incremental cost of $150,000, yielding a cost/QALY of $300,000. Challenges: Assigning utility values, cultural differences, and decision‑threshold acceptance.
Risk‑Sharing Agreement – concept #
financial partnership. Related terms: Outcomes‑based contracting, rebate clauses. Explanation: Contract where payer and manufacturer share financial risk based on drug performance. Example: Manufacturer refunds a portion of the cost if a diabetes drug fails to achieve HbA1c reduction targets. Challenges: Defining success metrics, data verification, and contract complexity.
Specialty Drug Certification – concept #
credentialing. Related terms: Pharmacy accreditation, competency training. Explanation: Formal recognition that a pharmacy meets specialized standards for handling, storing, and dispensing high‑complexity medications. Example: Certification requires demonstration of aseptic compounding for injectable biologics. Challenges: Maintaining competency, audit readiness, and cost of certification.
Therapeutic Drug Monitoring (TDM) – concept #
drug level tracking. Related terms: Pharmacokinetic sampling, dose adjustment. Explanation: Measuring drug concentrations in patients to optimize dosage of specialty agents with narrow therapeutic windows. Example: Monitoring trough levels of a monoclonal antibody to ensure efficacy while avoiding toxicity. Challenges: Timing of sample collection, assay availability, and interpretation variability.
Utilization Review (UR) – concept #
usage assessment. Related terms: Prospective review, retrospective review. Explanation: Systematic evaluation of medication orders to ensure appropriate, safe, and cost‑effective use of specialty drugs. Example: A UR flags a prescription for a high‑cost oncology drug that lacks required diagnostic confirmation. Challenges: Data latency, reviewer expertise, and provider resistance.
Value‑Based Formulary (VBF) – concept #
outcome‑driven list. Related terms: VBID, outcomes‑based contracting. Explanation: Formulary that prioritizes drugs delivering demonstrable clinical value relative to cost. Example: Including a gene‑therapy only after evidence shows long‑term remission rates exceed 80 %. Challenges: Evidence generation, dynamic updates, and stakeholder alignment.
Wholesale Distribution – concept #
supply chain tier. Related terms: Distributor contracts, cold‑chain logistics. Explanation: Movement of specialty drugs from manufacturers to specialty pharmacies through authorized distributors. Example: A distributor ships a batch of CAR‑T cells under temperature‑controlled conditions to the specialty pharmacy. Challenges: Maintaining integrity, regulatory compliance, and managing shortages.
eCommerce Pharmacy Platform – concept #
online dispensing. Related terms: Telepharmacy, digital adherence tools. Explanation: Web‑based interface allowing patients to order specialty medications, receive counseling, and track shipments. Example: A patient logs into a portal to schedule a home infusion of a biologic. Challenges: Ensuring security, verifying patient identity, and providing adequate clinical support.
Formulary Tiering – concept #
coverage stratification. Related terms: Copayment levels, step therapy. Explanation: Categorizing specialty drugs into tiers based on clinical value and cost, influencing patient cost‑sharing. Example: Tier 2 includes oral specialty agents with moderate copays; Tier 3 includes high‑cost injectables with higher cost‑sharing. Challenges: Patient confusion, tier creep, and equitable access.
Generic Substitution – concept #
cost reduction. Related terms: Therapeutic interchange, biosimilarity. Explanation: Replacing a brand‑name specialty drug with an FDA‑approved generic equivalent when available. Example: Substituting a generic version of a small‑molecule oncology drug for the brand product. Challenges: Limited generic options for biologics, provider acceptance, and insurance policies.
Health Savings Account (HSA) Integration – concept #
financial planning. Related terms: Flexible spending account, tax‑advantaged funds. Explanation: Allowing patients to use HSA funds to cover out‑of‑pocket costs for specialty medications. Example: A patient pays a high copay for a gene‑therapy using HSA balance. Challenges: Education on eligible expenses, timing of reimbursements, and coordination with pharmacy billing.
Immunogenicity Monitoring – concept #
immune response tracking. Related terms: Anti‑drug antibodies, safety assessment. Explanation: Evaluating the development of antibodies against biologic specialty drugs that may reduce efficacy or cause adverse events. Example: Testing for anti‑TNF antibodies in patients on infliximab. Challenges: Assay standardization, clinical interpretation, and cost of testing.
Joint Commission International (JCI) Standards – concept #
global quality benchmark. Related terms: Accreditation, patient safety. Explanation: International standards governing specialty pharmacy practices, focusing on safety, quality, and performance. Example: A specialty pharmacy in Europe adheres to JCI standards for sterile compounding. Challenges: Aligning with local regulations, resource allocation, and continuous improvement.
Key Clinical Data (KCD) – concept #
essential patient information. Related terms: Lab results, imaging studies. Explanation: Critical clinical parameters required to evaluate eligibility for a specialty medication. Example: Baseline eGFR for initiating a nephrotoxic oncology agent. Challenges: Timely acquisition, integration into pharmacy systems, and ensuring completeness.
Logistics Coordination – concept #
distribution management. Related terms: Supply chain, cold chain. Explanation: Planning and executing the movement of specialty drugs from pharmacy to patient, including shipping, tracking, and delivery. Example: Coordinating same‑day delivery of an infusion pump and medication to a patient’s home. Challenges: Temperature control, geographic barriers, and real‑time tracking.
Medication Access Programs – concept #
coverage facilitation. Related terms: Prior authorization, patient assistance. Explanation: Structured initiatives to assist patients in obtaining approved specialty therapies despite financial or administrative obstacles. Example: A dedicated access team works on appeals for denied biologic claims. Challenges: Staffing, complex payer policies, and patient frustration.
Network Contracting – concept #
service agreements. Related terms: Fee‑for‑service, value‑based contracts. Explanation: Negotiating terms with specialty pharmacies, infusion centers, and laboratories to deliver integrated care. Example: Contracting a specialty pharmacy for a fixed per‑patient fee for oncology services. Challenges: Aligning incentives, performance metrics, and renegotiation cycles.
Outpatient Parenteral Antimicrobial Therapy (OPAT) – concept #
home infusion service. Related terms: Home health, central line care. Explanation: Delivery of intravenous antibiotics to patients outside the hospital setting, often managed by specialty pharmacies. Example: A patient receives daily cefiderocol via a peripherally inserted central catheter at home. Challenges: Line infections, adherence monitoring, and coordination with clinicians.
Pharmacoeconomics – concept #
economic evaluation. Related terms: Cost‑utility analysis, budget impact. Explanation: Study of the value of specialty drugs by comparing costs to health outcomes. Example: Calculating the incremental cost‑effectiveness ratio (ICER) for a new CAR‑T therapy versus standard chemotherapy. Challenges: Data availability, modeling assumptions, and payer acceptance.
Pharmacogenomics – concept #
genetic‑based therapy. Related terms: Companion diagnostics, personalized medicine. Explanation: Using a patient’s genetic profile to guide selection and dosing of specialty medications. Example: Testing for CYP2D6 variants before prescribing a tyrosine kinase inhibitor. Challenges: Test accessibility, interpretation, and reimbursement.
Patient Education Materials – concept #
information resources. Related terms: Counseling scripts, instructional videos. Explanation: Structured tools to inform patients about administration, storage, and side‑effects of specialty drugs. Example: A brochure outlining self‑administration steps for an autoinjector. Challenges: Health literacy, cultural relevance, and updating content.
Quality Metrics – concept #
performance standards. Related terms: KPI, outcome measures. Explanation: Specific indicators used to assess the effectiveness, safety, and efficiency of specialty pharmacy services. Example: Metric – “percentage of patients achieving therapeutic drug levels within target range.” Challenges: Data capture, benchmark selection, and avoiding metric fatigue.
Rebate Management – concept #
financial negotiation. Related terms: Discount contracts, net price. Explanation: Process of obtaining and applying manufacturer rebates for specialty drugs to reduce overall cost to the payer. Example: Securing a 20 % rebate on a high‑cost biologic after meeting volume thresholds. Challenges: Transparency, timing of rebate receipt, and compliance with anti‑kickback statutes.
Remote Monitoring – concept #
telehealth oversight. Related terms: Digital adherence tools, wearable sensors. Explanation: Using technology to track patient adherence, side effects, and clinical parameters for specialty therapies outside the clinic. Example: A mobile app records injection dates for a subcutaneous biologic and alerts the pharmacy of missed doses. Challenges: Data security, patient engagement, and integration with EMR.
Risk Stratification – concept #
patient categorization. Related terms: Predictive analytics, case management. Explanation: Identifying patients at higher risk for adverse events or high utilization to prioritize interventions. Example: Flagging patients with renal impairment for closer monitoring when prescribing a nephrotoxic specialty drug. Challenges: Data quality, algorithm bias, and resource allocation.
Specialty Pharmacy Benefit Design – concept #
coverage architecture. Related terms: Tiered formularies, cost‑sharing. Explanation: Tailoring pharmacy benefits to address the unique cost and clinical considerations of specialty drugs. Example: Implementing a separate specialty benefit with dedicated copay assistance for high‑cost oncology agents. Challenges: Administrative complexity, patient communication, and cost containment.
Therapeutic Area Alignment – concept #
clinical focus. Related terms: Disease‑specific programs, specialty clinics. Explanation: Organizing specialty pharmacy services around specific therapeutic domains such as oncology, rheumatology, or rare diseases. Example: A dedicated oncology specialty pharmacy team manages infusion scheduling, lab monitoring, and patient education. Challenges: Staffing expertise, cross‑functional coordination, and maintaining up‑to‑date disease knowledge.
Utilization Forecasting – concept #
demand prediction. Related terms: Predictive modeling, inventory planning. Explanation: Estimating future specialty drug utilization to inform budgeting, inventory, and contracting decisions. Example: Forecasting a 15 % increase in demand for a new immunotherapy based on market adoption rates. Challenges: Data variability, sudden therapy breakthroughs, and regulatory changes.
Vendor Management – concept #
supplier oversight. Related terms: Contract negotiation, performance monitoring. Explanation: Managing relationships with manufacturers, distributors, and third‑party logistics providers for specialty drugs. Example: Evaluating a vendor’s temperature‑control capabilities before awarding a distribution contract. Challenges: Compliance, service level adherence, and cost negotiations.
White‑Box Analytics – concept #
transparent data analysis. Related terms: Open‑source modeling, explainable AI. Explanation: Analytical approaches that provide clear insight into how decisions about specialty drug coverage are derived. Example: Using a white‑box model to show the impact of a specialty drug on total cost of care. Challenges: Data integration, model complexity, and stakeholder trust.
Zero‑Day Inventory – concept #
immediate availability. Related terms: JIT inventory, emergency dispensing. Explanation: Maintaining a minimal stock of critical specialty medications to fulfill urgent prescriptions without delay. Example: Keeping a single vial of a life‑saving enzyme replacement on hand for emergency use. Challenges: Shelf‑life constraints, cold‑chain maintenance, and forecasting accuracy.